drugset / Trial / NCT02846545
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
Timeline
- Start
- 2016-08-26
- Primary completion
- 2019-05-21
- Completion
- 2021-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golimumab | Monoclonal antibody | — | Subcutaneous |